Cold Sore Treatment Market 2020 Study of Top Key Players: Squarex, Merix Pharmaceutical Corp, AiCuris, GlaxoSmithKline plc, Medivir AB, Renaissance Pharma, Inc

Global cold sore treatment market is expected to grow at a healthy CAGR in the forecast period of 2019-2026. Growing incidence ocular surface injuries as it can contribute to the neurotrophic keratitis and development of advanced therapies and treatment are the key factors for market growth

Get Sample Report + All Related Graphs & Charts @
https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cold-sore-treatment-market
Key Market Players:

Few of the major competitors currently working in the global cold sore treatment market are Squarex, Merix Pharmaceutical Corp, AiCuris, GlaxoSmithKline plc, Medivir AB, Renaissance Pharma, Inc, Deerfield, Otsuka Holdings Co.,Ltd, Mylan N.V., Teva Pharmaceutical Industries Ltd, Cipla Inc, Alembic Pharmaceuticals Limited, Zydus Cadila, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd, HETERO, Novartis AG, Tolmar Pharmaceuticals, Inc, and others.

Global Cold Sore Treatment Market By Types (Herpes Simplex Type 1 Virus, Herpes Simplex Type 2 Virus), Treatment (Non pharmacological Treatment, Pharmacological Treatment), Drugs (Antiviral Ointments, Oral Antiviral Agents), Route of Administration (Oral, Topical and Others), End- Users (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2026

Competitive Analysis:

Global cold sore treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global cold sore treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Definition: Global Cold Sore Treatment Market

Cold sore also known as herpes labialis is a viral infection cause by herpes simplex virus. It is characterized by red, fluid-filled blisters or ulcers that appear on the lips and around the mouth. These blisters are often appearing as patches, when it breaks a crust forms over the resulting sore.

According to the statistics published by WebMD LLC, it is estimated about 40% of U.S. adult population gets repeated cold sores. High demand of novel treatment and huge investment on research and development are drivers for market growth.

Market Drivers

Growing prevalence of cold sore worldwide is drive the market
Huge financial support to the researchers for developing novel intervention is boosting the market growth
High demand of disease specific novel treatment can also act as a market driver
Advancement in treatment and incorporation of novel formulation can improve the ease the pain of cold sores is also act as factors that drive the market
Market Restraints

Patent expiry of branded drugs and introduction of generics is also acting as a challenging factor for the growth of this market
Low healthcare budget in some developing countries is hamper the market growth

Grab Your Report at an Impressive 30% Discount! Please click Here@
https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cold-sore-treatment-market

Segmentation: Global Cold Sore Treatment Market

By Strain Type

Herpes Simplex Type 1 Virus
Herpes Simplex Type 2 Virus
By Treatment

Non pharmacological Treatment
Pharmacological Treatment
By Drugs

Antiviral Ointments
Penciclovir
Docosanol
Oral Antiviral Agents
Acyclovir
Famciclovir
Valacyclovir
Others
By Route of Administration

Oral
Topical
Others
By End Users

Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Key Developments in the Market:

In August 2019, Merix Pharmaceutical Corp has launched RELEEV which contains VIRACEA, a proprietary botanical extract formulation of Echinacea extract and antiseptic Benzalkonium Chloride for the treatment of cold sores. This drug claims that it eases the pain of cold sores in just 3 to 10 minutes, relieves other symptoms within 24 hours. The launch of this drug provides a novel topical treatment and majao advances that offer complete heal of this condition
In February 2019, Squarex, reported a positive clinical results of SQX770, a topical formulation of immunomodulator squaric acid dibutyl ester for the treatment of recurrent cold sores (herpes labialis) and other infections caused by Herpes Simplex Viruses. The trial demonstrated that the drug was safe and effective in preventing cold sore outbreaks. If approved, SQX770 would be the first and only drug on the market to prevent cold sores throughout the United States.

Reasons to Purchase this Report

Current and future of global cold sore treatment market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
Regions/Countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

This release was published on openPR.